Skip to content

Jefferies retains #39;buy#39; call on Sun Pharma with 26% upside, stays bullish on Concert deal

Jefferies expects Sun Pharma to leverage its existing field force to market this product and incremental spend will largely be towards promotion of the product. It forecasts that Deuruxolitinib can achieve sales of around USD 765 million in the US EU market by 2031.

Read More

​ Jefferies expects Sun Pharma to leverage its existing field force to market this product and incremental spend will largely be towards promotion of the product. It forecasts that Deuruxolitinib can achieve sales of around USD 765 million in the US EU market by 2031. Jefferies expects Sun Pharma to leverage its existing field force to market this product and incremental spend will largely be towards promotion of the product. It forecasts that Deuruxolitinib can achieve sales of around USD 765 million in the US EU market by 2031.  Moneycontrol Latest News Read More  

Leave a Reply

Your email address will not be published. Required fields are marked *

en_USEnglish